ATF4 and Miyoshi myopathy: Although the amounts of ATF3 and ATF4 mRNA in MM cells before treatment could be potential predictive biomarkers of the efficacy of BD therapy or of other BTZ-containing regimens, clinical utility needs to be confirmed by large-scale replication studies in patients with MM.